SOUTH SAN FRANCISCO, Calif. – April 25, 2001 – AGY Therapeutics, Inc. today announced that Thorsten Melcher, Ph.D., vice president of research at AGY, presented data today at the IBC conference on Target Validation in San Diego, CA.

"The work presented here demonstrates the power and utility of AGY's functional genomics platform to identify and validate critical pathways in stroke and other neurological disorders," said Karoly Nikolich, Ph.D., founder and chief executive officer of AGY.

The presentation included data from collaborative studies between AGY and Dr. Tadeusz Wieloch at the Wallenberg Neuroscience Center (Lund, Sweden), in which neuroprotective genes were identified, functionally characterized and validated within a short time-frame.

"AGY continues to validate many potential drug targets for stroke, Alzheimer's disease and other diseases to add to our drug discover efforts," added Dr. Nikolich.

AGY's proprietary imAGYne functional genomics platform enables the generation and collection of regulated genes from selected biological models. The imAGYne platform has been applied to the analysis of models of stroke and neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's disease and depression.

AGY Therapeutics, Inc. is a privately held biopharmaceutical company focused on developing therapeutic products for the treatment of diseases of the central nervous system. With its proprietary imAGYne, imArrays and imFormatics platforms, AGY has built a unique knowledge base of the neuroprotective capacities and vulnerabilities of the nervous system.

This news release contains forward-looking statements about future research and development efforts. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that further research into these genes may not go forward as planned or that future scientific data on these genes may not provide supportive data for the diseases we are targeting.

About AGY l Research & Development l Investors & Partners l AGY News l Career Opportunities l Contact Us